Myriad Genetics guidance still looks conservative, says Cowen Cowen believes Myriad Genetics increased guidance remains conservative citing improved margins and tax rates, and assumptions that include no increase to the Companion Diagnostics revenue range and expectations that BART percentage usage remains the same. Shares are Outperform rated.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Myriad Genetics advises prior BRACAnalysis news release be disregarded Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.